Edwards Lifesciences (NYSE:EW) Updates Q3 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its third quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.710-0.770 for the period, compared to the consensus EPS estimate of 0.740. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Edwards Lifesciences also updated its FY 2026 guidance to 2.950-3.050 EPS.

Edwards Lifesciences Stock Performance

NYSE EW opened at $87.75 on Friday. The company’s 50 day moving average is $87.70 and its 200-day moving average is $83.89. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a market cap of $50.52 billion, a P/E ratio of 46.82, a price-to-earnings-growth ratio of 2.12 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences will post 3 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on EW shares. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. BTIG Research raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Evercore reaffirmed an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research note on Wednesday, April 1st. Finally, Citigroup boosted their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $99.04.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 45,577 shares of company stock worth $3,855,527. Insiders own 0.31% of the company’s stock.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Leerink Partners upgraded Edwards Lifesciences (EW) from market perform to outperform and set a $101 price target, implying meaningful upside from recent levels. Leerink Partners upgrade
• Positive Sentiment: The company reported strong Q2 results, with revenue up 13.6% year over year to $1.74 billion and adjusted EPS of $0.78, both ahead of Wall Street estimates. Q2 results press release
• Positive Sentiment: Management raised its full-year sales outlook to $6.6 billion-$6.9 billion and increased the low end of guidance, signaling confidence in continued demand for its heart-valve and transcatheter therapies. WSJ guidance update
• Positive Sentiment: Investors also responded favorably to strong sales momentum in the core TAVR franchise and improving expectations for TMTT, which helped push the stock up in extended trading after the earnings release. Reuters earnings article
• Neutral Sentiment: Analysts’ recent coverage remains constructive overall, with multiple firms maintaining or issuing positive targets around the $100-$110 range, reinforcing a favorable sentiment backdrop for the stock. Analyst targets overview

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds have recently added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $266,000. NewEdge Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after acquiring an additional 2,665 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its position in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after purchasing an additional 1,065 shares during the period. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.